

Resource Summary Report

Generated by [dkNET](#) on Aug 20, 2026

TCF1/TCF7 (C63D9) Rabbit mAb (Alexa Fluor® 647 Conjugate)

RRID:AB_2797631

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 6709, RRID:AB_2797631

Antibody Information

URL: http://antibodyregistry.org/AB_2797631

Proper Citation: Cell Signaling Technology Cat# 6709, RRID:AB_2797631

Target Antigen: TCF1/TCF7

Host Organism: rabbit

Clonality: recombinant monoclonal

Comments: Applications: FC-FP

Antibody Name: TCF1/TCF7 (C63D9) Rabbit mAb (Alexa Fluor® 647 Conjugate)

Description: This recombinant monoclonal targets TCF1/TCF7

Target Organism: mouse, human

Clone ID: Clone C63D9

Antibody ID: AB_2797631

Vendor: Cell Signaling Technology

Catalog Number: 6709

Record Creation Time: 20250820T023053+0000

Record Last Update: 20250820T134716+0000

Ratings and Alerts

No rating or validation information has been found for TCF1/TCF7 (C63D9) Rabbit mAb (Alexa Fluor® 647 Conjugate).

No alerts have been found for TCF1/TCF7 (C63D9) Rabbit mAb (Alexa Fluor® 647 Conjugate).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 42 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Geng H, et al. (2026) Unleashing T cell surveillance for the eradication of quiescent persister tumor cells resistant to neoadjuvant chemotherapy. *Developmental cell*, 61(5), 995.

Gago da Graça C, et al. (2026) B cell-derived type I interferon sustains T cell functionality upon strong TCR stimulation during chronic infection. *Immunity*.

Freeburg NF, et al. (2026) The critical role of the endogenous immune compartment after CAR T cell therapy in recurrent GBM. *Cell*.

Fukui T, et al. (2026) A hierarchical Rorc(?t) cis-regulatory cascade orchestrates differentiation of ROR?t? innate immune cells. *Immunity*, 59(4), 953.

Shen J, et al. (2026) Krüppel-like factors 2 and 3 regulate T cell exhaustion by directing T cell residency and migration. *Immunity*, 59(5), 1287.

Geng S, et al. (2026) Krüppel-like factor 2 programs early exhausted T cell states and restrains antiviral immunity. *Immunity*, 59(5), 1306.

Ma K, et al. (2025) Succinate preserves CD8+ T cell fitness to augment antitumor immunity. *Immunity*.

Herbst M, et al. (2025) Cancer-cell-derived cGAMP limits the activity of tumor-associated CD8+ T cells. *Cell reports*, 44(4), 115510.

van der Heide V, et al. (2025) Prolonged but finite antigen presentation promotes reversible defects of "helpless" memory CD8+ T cells. *Immunity*, 58(7), 1742.

Köksal H, et al. (2025) Pre-existing intratumoral stem-like CD8+ T cells drive radiotherapy-induced tumor immunity. *Cell reports*, 44(4), 115566.

Qiu Y, et al. (2025) Mannose metabolism reshapes T cell differentiation to enhance anti-tumor immunity. *Cancer cell*, 43(1), 103.

Webb L, et al. (2025) Membrane-bound IL-15 co-expression powers a potent and persistent CD70-targeted TRuC T-cell therapy. *Frontiers in immunology*, 16, 1609658.

Wei H, et al. (2025) AKR1D1 suppresses liver cancer progression by promoting bile acid metabolism-mediated NK cell cytotoxicity. *Cell metabolism*, 37(5), 1103.

Xiao Z, et al. (2025) Engineered T cells stimulate dendritic cell recruitment and antigen spreading for potent anti-tumor immunity. *Cell reports. Medicine*, 6(9), 102307.

Guak H, et al. (2024) Transcriptional programming mediated by the histone demethylase KDM5C regulates dendritic cell population heterogeneity and function. *Cell reports*, 43(8), 114506.

Wang L, et al. (2024) T-bet deficiency and Hic1 induction override TGF- β -dependency in the formation of CD103⁺ intestine-resident memory CD8⁺ T cells. *Cell reports*, 43(6), 114258.

Cheng M, et al. (2024) ROR γ is required for expansion and memory maintenance of ILC1s via a lymph node-liver axis. *Cell reports*, 43(2), 113786.

Kumar S, et al. (2024) Uncovering therapeutic targets for macrophage-mediated T cell suppression and PD-L1 therapy sensitization. *Cell reports. Medicine*, 5(9), 101698.

Gubser PM, et al. (2024) Aerobic glycolysis but not GLS1-dependent glutamine metabolism is critical for anti-tumor immunity and response to checkpoint inhibition. *Cell reports*, 43(8), 114632.

Wang K, et al. (2024) Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8⁺ T cells. *Cancer cell*, 42(9), 1582.